FDA AMR Public Workshop
FDA AMR Public Workshop is announcing a public workshop regarding scientific issues in clinical development of medical products (i.e., human drugs, therapeutic biological products, and medical devices) for prophylaxis and/or treatment of acute antibody mediated rejection (AMR) in kidney transplant recipients. This public workshop is intended to provide information for and gain perspective from health care providers, academia, and industry on various aspects of development of medical products for prophylaxis and/or treatment of acute AMR in kidney transplant recipients, including clinical trial design and endpoints. The input from this public workshop will help in developing topics for further discussion. For more information, please visit www.fda.gov/Drugs/NewsEvents/ucm206132.htm
If you have newsworthy information to add to the ASHI Web site, please contact kmiranda@ahint.com for consideration.